Wegovy (injection) is FDA-approved for adults and children over 12 with obesity or weight-related conditions like high cholesterol, type 2 diabetes, or high blood pressure
Qualifying coverage may include a standalone Medicare drug plan, certain Medicare Advantage plans with drug coverage, Special Needs Plans, employer or union group plans, and the Limited Income Newly Eligible Transition program
Monomeric C-reactive protein: current perspectives for utilization and inclusion as a prognostic indicator and therapeutic target
Ozempic and Wegovy both contain semaglutide, and, like Mounjaro and Zepbound, the distinction is between Type 2 diabetes brands and obesity brands
Suppl 1 (2009): 149
We're your partners every step of the way, ensuring your path to weight loss is safe, effective, and empowering